Extensively Drug-Resistant Tuberculosis
"Extensively Drug-Resistant Tuberculosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
| Descriptor ID |
D054908
|
| MeSH Number(s) |
C01.252.410.040.552.846.775.500
|
| Concept/Terms |
Extensively Drug-Resistant Tuberculosis- Extensively Drug-Resistant Tuberculosis
- Extensively Drug Resistant Tuberculosis
- Extremely Drug-Resistant Tuberculosis
- Drug-Resistant Tuberculoses, Extremely
- Drug-Resistant Tuberculosis, Extremely
- Extremely Drug Resistant Tuberculosis
- Extremely Drug-Resistant Tuberculoses
- Tuberculoses, Extremely Drug-Resistant
- Tuberculosis, Extremely Drug-Resistant
- Tuberculosis, Extremely Drug Resistant
- XDR-TB
- Tuberculosis, Extensively Drug-Resistant
- Drug-Resistant Tuberculoses, Extensively
- Drug-Resistant Tuberculosis, Extensively
- Extensively Drug-Resistant Tuberculoses
- Tuberculoses, Extensively Drug-Resistant
- Tuberculosis, Extensively Drug Resistant
|
Below are MeSH descriptors whose meaning is more general than "Extensively Drug-Resistant Tuberculosis".
Below are MeSH descriptors whose meaning is more specific than "Extensively Drug-Resistant Tuberculosis".
This graph shows the total number of publications written about "Extensively Drug-Resistant Tuberculosis" by people in this website by year, and whether "Extensively Drug-Resistant Tuberculosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2018 | 5 | 0 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Extensively Drug-Resistant Tuberculosis" by people in Profiles.
-
Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 May 30; 74(10):1736-1747.
-
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid. BMJ Case Rep. 2021 Dec 07; 14(12).
-
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open. 2021 12 03; 11(12):e051521.
-
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. Reply. N Engl J Med. 2020 06 11; 382(24):2377.
-
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020 03 05; 382(10):893-902.
-
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
-
Multidrug-resistant tuberculosis outbreak in South Africa. Lancet Infect Dis. 2019 02; 19(2):134-135.
-
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018 09; 6(9):699-706.
-
Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018 07; 18(7):779-787.
-
Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat Genet. 2018 02; 50(2):307-316.